EMA's CHMP recommends authorization of two new COVID-19 treatments
The European Medicines Agency said today that its human medicines committee (CHMP) has recommended authorization of two new COVID-19 treatments.
Xevudy (sotrovimab), a monoclonal antibody, is for the treatment of COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. The applicant is GlaxoSmithKline (LSE: GSK), which developed the medicine together with Vir Biotechnology.
Xevudy is the third monoclonal antibody recommended in the European Union for treating COVID-19 and its approval follows those of South Korean firm Celltrion Healthcare’s (Kosdaq: 068270) Regkirona (regdanvimab) and Ronapreve (casirivimab/imdevimab), from Swiss pharma giant Roche (ROG: SIX), in November.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze